Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology Seen as Takeover Target After Strong Cancer Drug Data - TheStreet
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
UBS Has Nine Biotech Buyout and Merger Candidates – 24/7 Wall St.
Puma and CANBridge cancel licensing deal for $20m
Opinion: 15 biotech stocks to put on your watch list now - MarketWatch
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
A Licensing Agreement Won't Protect This Biotech From A Takeover | Investor's Business Daily
5 Best Biotech Stocks for 2018 | InvestorPlace
Puma Bio: Now Or Never. I Go With Never (NASDAQ:PBYI) | Seeking Alpha
10 Takeover Targets of 2018
Puma Biotech's new cancer drug Nerlynx suffered a terrible quarter. What gives? | Fierce Pharma
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotech punts near $300 million on Takeda discard
